Latest Updates

Pilot Chemical Announces Leadership Transition

Pilot Chemical Corp., a privately owned and independent global specialty chemical company, announced today that Pamela Butcher will step down from her CEO role effective January 1, 2021. She will remain on the Pilot Board of Directors and serve as a special advisor to the Chairman.

October 5, 2020

Gelest Shareholders Close Sale to Mitsubishi Chemical | Jonathan Goff Appointed as Gelest Chief Technology Officer

Gelest announced today it has completed the sale of Gelest Intermediate Holdings to Mitsubishi Chemical America, Inc. (MCA; Head office: New York, the United States; President: Steve Yurich), the U.S. subsidiary of Mitsubishi Chemical Corporation (MCC; Head office: Chiyoda-ku, Tokyo; President: Masayuki Waga). Gelest Intermediate Holdings is the parent of Gelest, Inc. and Bimax, Inc. (Gelest; Head office: Pennsylvania, the United States; Chair: Barry Arkles, CEO: Ken Gayer). The transaction, which was announced on April 30, 2020, has cleared all regulatory approvals.

October 5, 2020

Pilot Chemical Adds EPA Emerging Viral Pathogen Claim to Eight Products

Pilot Chemical Corp. is pleased to announce that through its subsidiary Mason Chemical Company, it has received EPA acceptance to add an emerging viral pathogen claim to the labels of eight products from the company’s EPA-registered quaternary ammonium compound and active ingredient line, under its Maquat® and Maguard® brands.

October 1, 2020

CJB and National FFA Launch a Cooperative Venture

The CJB companies (CJB Industries, Inc. and CJB Applied Technologies, LLC) have announced a cooperative venture with National FFA to benefit the companies who support National FFA as well as the National FFA itself.

September 30, 2020

SOCMA Adds Another Five Members to its Ranks

The Society of Chemical Manufacturers & Affiliates (SOCMA) is pleased to announce the addition of five more companies to the association, expanding the total number of new members to 16 in the first three quarters of 2020. SOCMA’s Board of Governors last week approved chemical manufacturer Sofix and service providers Anchin, New York Center for Innovation, POWER Engineers and Rockwell Automation.

September 23, 2020

Humanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigen’s COVID-19 Therapeutic Candidate Lenzilumab

Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper response called ‘cytokine storm,’ and Lonza today announced a strategic collaboration to expand the manufacturing capacity for lenzilumab, currently in Phase 3 clinical trials for COVID-19, in advance of potential Emergency Use Authorization in 2020 and subsequent commercialization.

September 16, 2020